RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 Etanercept Proves Clinically Superior to Discontinuation: Results from the DOSERA Trial
JF MD Conference Express
YR 2012
FD SAGE Publications
VO 12
IS 19
SP 16
OP 17
DO 10.1177/155989771219012
UL http://mdc.sagepub.com/content/12/19/16.abstract
AB This article discusses results from the late-breaking Study Comparing the Effect on Disease Activity When Reducing or Discontinuing Etanercept in Subjects with RA [DOSERA; NCT00858780]. The results showed that in patients with rheumatoid arthritis and stable low disease activity on methotrexate plus etanercept, continued treatment with etanercept at 25 or 50 mg/week provides a significantly higher likelihood of maintaining a stable disease state over 48 weeks than placebo.